Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (XNCR) is a clinical-stage biopharmaceutical leader pioneering engineered antibody therapeutics for cancer and autoimmune diseases through its proprietary XmAb® technology platform. This page serves as the definitive source for tracking Xencor's latest developments, providing investors and industry observers with timely updates on scientific advancements and business milestones.
Access comprehensive coverage of Xencor's clinical trial progress, regulatory updates, and strategic collaborations with global pharmaceutical partners. Our curated news collection features verified press releases and analysis-worthy developments including technology licensing agreements, pipeline expansions, and research breakthroughs in antibody engineering.
Key content focuses include updates on XmAb® platform innovations, partnership announcements with major drug developers, clinical study results for novel cancer treatments, and progress in autoimmune therapy candidates. All content is rigorously vetted to ensure relevance to investment decision-making and scientific credibility.
Bookmark this page for streamlined access to Xencor's evolving story in biotherapeutic innovation. Check regularly for critical updates on therapeutic candidates moving through clinical development phases and new applications of its protein engineering expertise.
Xencor (XNCR) has priced its public offering of common stock and pre-funded warrants, aiming to raise $175 million. The offering includes 6,635,112 shares at $18.00 per share and 3,088,888 pre-funded warrants at $17.99 each. Underwriters have a 30-day option to purchase up to 1,458,600 additional shares. The clinical-stage biopharmaceutical company plans to use the proceeds for general corporate purposes, including research and development, capital expenditures, and working capital. The offering is expected to close around September 12, 2024, subject to customary conditions.
Xencor (Nasdaq: XNCR), a clinical-stage biopharmaceutical company, has announced a proposed public offering of common stock and pre-funded warrants. The offering includes a 30-day option for underwriters to purchase up to an additional 15% of shares. Leerink Partners, Raymond James, and RBC Capital Markets are acting as joint book-running managers, with Wedbush PacGrow as co-manager.
The company plans to use the net proceeds for general corporate purposes, including research and development, capital expenditures, and working capital. The offering is being made through an automatic shelf registration statement on Form S-3, with a preliminary prospectus supplement to be filed with the SEC.
Xencor, Inc. (NASDAQ: XNCR) announced four new XmAb® programs for treating autoimmune diseases and provided updates on early-stage oncology programs. Key highlights include:
1. XmAb942: Phase 1 study for IBD to start Q4 2024, with data expected H1 2025.
2. Plamotamab (CD20 x CD3) and XmAb657 (CD19 x CD3): To be evaluated for autoimmune diseases, with studies starting in 2025.
3. XmAb819 (ENPP3 x CD3): Showing encouraging clinical activity in advanced clear cell renal cell carcinoma.
4. XmAb808 (B7-H3 x CD28): Demonstrating PSA declines in metastatic castration-resistant prostate cancer patients.
The company aims to leverage its protein engineering strengths to increase clinical success opportunities.
Xencor (NASDAQ: XNCR), a clinical-stage biopharmaceutical company, has announced a Research & Development Webcast and Conference Call scheduled for Monday, September 9, 2024, at 8:00 a.m. ET. The event will introduce new XmAb® programs for treating autoimmune diseases and provide updates on oncology programs, including:
- XmAb819 (ENPP3 x CD3) for advanced clear cell renal cell carcinoma
- XmAb808 (B7-H3 x CD28) for advanced solid tumors
The webcast can be accessed through the Investors section of Xencor's website. A recording will be available for at least 30 days after the event.
Xencor (NASDAQ:XNCR) reported Q2 2024 financial results and provided updates on its clinical-stage programs. Key highlights include:
- Cash position of $585.0 million as of June 30, 2024
- Q2 2024 revenues of $17.0 million, down from $45.5 million in Q2 2023
- Net loss of $66.0 million ($1.07 per share) in Q2 2024
- Advancing clinical trials for XmAb819, XmAb808, and XmAb541
- Regained worldwide rights to plamotamab
- Expects to end 2024 with $475-$525 million in cash, funding operations into 2027
The company continues to focus on developing bispecific T-cell engagers and other XmAb candidates, with plans to announce new clinical development candidates in the coming months.
Xencor (NASDAQ: XNCR) announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen Biotech terminated its rights under their collaboration agreement. Xencor had advanced plamotamab through Phase 1 clinical trials targeting hematologic cancers. Despite Janssen's withdrawal, it retains rights to develop and commercialize other B-cell targeting CD28 bispecific antibodies, JNJ-9401 and JNJ-1493, which are in Phase 1 clinical trials for prostate cancer and B-cell malignancies respectively.
Xencor emphasizes that plamotamab is Phase 2 ready and subcutaneously administered, highlighting its potential to address unmet medical needs. The company remains eligible for milestone payments and royalties from Janssen's ongoing projects and has the option to co-fund development costs for increased royalty benefits.
Xencor, a clinical-stage biopharmaceutical company, reported financial results for the first quarter ended March 31, 2024, focusing on bispecific T cell engagers for cancer treatment. Recent highlights include the advancement of multiple oncology programs, FDA approval of Ultomiris, and positive results in malaria prevention. The company appointed a new CFO and provided financial guidance with a cash balance of $646.7 million as of March 31, 2024. Despite a decrease in revenues and an increased net loss compared to the previous year, Xencor remains well-funded.
FAQ
What is the current stock price of Xencor (XNCR)?
What is the market cap of Xencor (XNCR)?
